BACKGROUND: An important goal of The Paris System for Reporting Urinary Cytology (TPS) is to reduce unnecessary atypical diagnoses given to urinary tract cytology (UTC) specimens. Since implementation of TPS at the study institution in 2016, the institutional atypical rate has declined only slightly. The authors speculated that TPS might not have had an immediate impact because several faculty members were involved in TPS committees and because TPS contains elements that already had been integrated into institutional practice. To identify factors contributing to alterations in the institutional atypical rate, the authors examined their practice over the last 22 years. METHODS: UTC specimens submitted to the study laboratory between August 11, 1995, and August 10, 2017, were identified. Specimens were linked to the responsible pathologist, specimen diagnosis and type, association with high-grade urothelial carcinoma, and relevant cytomor- 
INTRODUCTION
The Johns Hopkins Hospital Template (JHHT) for reporting urinary cytology was established at the study institution in 2006 to standardize urinary tract cytology (UTC) specimen diagnoses among our pathologists. [1] [2] [3] Although this system did not define specific criteria for each diagnostic category, it did generate increased discussion and scrutiny regarding how UTC specimens were evaluated at the study institution (Dorothy Rosenthal, oral communication, January 2018). The performance of the template was analyzed and published in a series of article in 2013 and stimulated discussions at the 18th International Congress of Cytology, which was held in Paris in May 2013: the beginnings of what would be The Paris System for Reporting Urinary Cytology (TPS). [4] [5] [6] One important goal of TPS is to reduce unnecessary atypical diagnoses. As a result, since its release in 2016, numerous institutions have investigated the impact TPS has had on their practice and atypical diagnosis rate. [7] [8] [9] [10] [11] [12] [13] [14] The JHHT was replaced by TPS at the study institution in August 2016, but did not appear to greatly reduce the institutional atypical rate in the first year when compared with the year immediately before TPS. We speculated that TPS might not have had an immediate impact on the study institution because several faculty members were involved in TPS committees between 2013 and 2016, and because TPS contains elements of the JHHT. To investigate this hypothesis further, we examined our institutional atypical rate over a large period of time to determine the factors that contributed toward alterations in the institutional atypical rate.
MATERIALS AND METHODS
Institutional review board approval and a consent waiver were obtained for this study.
The pathology archives were searched for in-house UTC specimens submitted to the cytopathology laboratory between August 11, 1995, and August 10, 2017 . During this period, 21 board-certified cytopathologists were responsible for cases in our laboratory. Specimens were prepared using either BD SurePath liquid-based preparations (Becton, Dickinson and Company, Franklin Lakes, New Jersey) or as cytospin preparations over the study period.
Diagnoses were assigned an internal score by the responsible pathologist for the purposes of cytologichistologic correlation; score categories were referred to as "nondiagnostic," "atypical," "suspicious," and "high-grade urothelial carcinoma" (HGUC) for consistency in the current study. The specific diagnostic terminology during use of the JHHT or TPS was as follows: for "benign," the categories of "negative for urothelial atypia or malignancy" (JHHT) and "negative for HGUC" (TPS) were used; for "atypical," the categories of "atypical urothelial cells of undetermined significance" (JHHT) and "atypical urothelial cells" (TPS) were used; and for "suspicious," the categories of "atypical urothelial cells, cannot exclude HGUC" (JHHT) and "suspicious for HGUC" (TPS) were used.
Statistical Analysis
The Fisher exact test was used for statistical comparisons.
RESULTS

A Gradual Decline in the Institutional Atypical Rate Occurred After the Establishment of the JHHT
The overall rate in UTC specimen diagnoses among all pathologists was plotted by year (Fig. 1A) . Although the rates of malignant and suspicious diagnoses tracked closely together over time, the rate of atypical diagnoses was approximately 20% to 25% until 2002, after which an increase to a peak of 30% to 35% occurred during the years 2004 and 2005. After this peak, the rate declined to a plateau of 10% to 20%. This decline was found to be associated closely in time with the establishment of the JHHT, which was the first standardized nomenclature system used for UTC specimens at the study institution. Both the increase and decrease in atypical rates between the years 2002 and 2008 occurred in a gradual fashion (Fig. 1B) . The institutional atypical rate was plotted against the volume of UTC specimens submitted to the study laboratory. Between 1995 and 2005, the number of in-house UTC specimens evaluated by the laboratory more than doubled and then plateaued in the year 2003, which corresponded to an increase in the institutional atypical rate that occurred over this period of time ( Fig. 2A) Urologist practice patterns may impact the atypical rate if specimens with an increasing amount of complexity are submitted to the laboratory. For example, beginning in the early 2000s, several important studies were published regarding the use of a single, postoperative, intravesical installation of chemotherapy agents after transurethral resection of bladder tumors. To the best of our knowledge, the effects of these agents, such as mitomycin C, epirubicin, and doxorubicin, on the performance of urinary cytology have not yet been well established, but may have caused atypical alterations and thus increased specimen complexity. 15, 16 In addition, urinary tract washings evaluating upper tract lesions may have higher indeterminate rates due to instrumentation artifacts, as well as pathologist concern over the impact of a definitive diagnosis. We evaluated several factors to determine whether the increase in the institutional atypical rate might have occurred due to an increase in specimen complexity over time.
We plotted the atypical rate with the number of voided urine (VU) UTC specimens and the VU specimen atypical rate over time ( Fig. 2A) . The percentage of VU specimens declined slightly from 2000 to 2012; this apparently had no effect on the increase and decrease in the atypical rate over the same period. In addition, the atypical rate among VU specimens closely tracked the overall institutional atypical rate. Thus, UTC specimen type did not appear to influence the institutional atypical rate.
Patients with HGUC may be at risk of disease recurrence and experience an increased rate of atypical diagnoses due to the presence of degenerated HGUC cells; a history of HGUC also may bias a pathologist's interpretation of atypical cells in a UTC specimen toward an atypical diagnosis. There was an increase in the number of specimens submitted from patients diagnosed with HGUC during the study period (Fig. 2B) ; however, the number of these patients receiving atypical diagnoses closely mirrored the institutional atypical rate. The institutional atypical rate (blue triangles) compared with the volume of urinary tract cytology (UTC) specimens submitted to the study laboratory (Lab) (green diamonds; right y-axis scale), the percentage of voided urine (VU) specimens (purple circles), and the VU specimen atypical rate (red squares). The VU atypical rate closely followed the overall institutional atypical rate. (B) The percentage of UTC specimens from complex patients over time (green squares) compared with the institutional atypical rate (blue triangles) and the atypical rate of specimens from complex patients (red circles) over time. Complex patients were those who were found to have high-grade urothelial carcinoma on tissue biopsy or UTC during the study period. The atypical rate among complex patients mirrored that of the overall institutional atypical rate (blue triangles).
Atypical Rates of Individual Pathologists Peaked With the Institutional Atypical Rate
Pathologists have distinct practice patterns, and thus atypical rates may vary between individuals. The addition or subtraction of a pathologist to a practice may increase or decrease the overall laboratory atypical rate. We examined the individual atypical rates of 7 deidentified pathologists who were on staff during the peak of the institutional atypical rate (the year 2005); the atypical rates ranged from 22% to 43%. Three of the pathologists with the highest atypical rates were on staff for short periods of time (5 years), which coincided with the increase in the institutional atypical rate (Fig. 3) . However, only one pathologist (pathologist 3) (Fig. 3) joined the practice just before the increase in the atypical rate. It is difficult to determine the extent to which the high rates of atypical diagnoses among pathologists 8 and 11 contributed to the institutional peak, because the relatively high institutional atypical rate over this period (a "culture of atypia") that existed when these pathologists joined the practice may have influenced them to have higher rates of atypical diagnoses.
To examine this phenomenon further, we compared the 2005 atypical rates among these 7 pathologists and their overall atypical rates. For all 7 pathologists, the 2005 atypical rates represented a higher rate than their overall rates, with the exception of pathologist 3 (Fig. 3) . In addition, we plotted the atypical rates of 2 individual pathologists over time and found that their rates of atypical diagnoses increased and decreased along with the institutional rate. This finding suggests that increases and decreases in the institutional atypical rate may have been due to a collective culture among cytopathologists rather than the practice patterns of individual pathologists (Fig. 4) .
Patients With a History of an Atypical Diagnosis Were More Likely to Be Classified as Atypical
Over time, patients evaluated by UTC became more likely to have a history of an atypical diagnosis (Fig. 5) . It is interesting to note that this effect was observed in 2002, before the increase in the institutional atypical rate occurred in 2003. More important, this effect was more pronounced among specimens with an atypical diagnosis, indicating a practice shift in which patients with a history of an atypical diagnosis were more likely to have a subsequent specimen diagnosed as atypical. After the 2005 peak in the institutional atypical rate, the percentage of specimens with a prior atypical diagnosis plateaued, but a history of an atypical diagnosis remained associated with a subsequent diagnosis of atypia.
Known Changes in the Definition of "Atypical" Do Not Explain Alterations in the Institutional Atypical Rate Over Time
The establishment of the JHHT coincided with a decrease in the institutional atypical rate. This system standardized certain practice patterns that existed among certain individual cytopathologists before the JHHT, such as UTC specimens being classified as atypical if they contained BK polyomavirus cytopathic effect, whereas VU specimens were classified as atypical if tissue fragments were present. [17] [18] [19] We examined the institutional atypical rate over time with the subtraction of these specimens (Fig. 6 ). The absence of these specimens did not greatly alter the shape of the atypical curve, indicating that they did not contribute toward the increase and decrease in the institutional atypical rate before and after 2005. Parenthetically, the JHHT was introduced without specific criteria having been agreed on by the pathologists and cytotechnologists in the study institution. In contrast, TPS has specific, well-defined criteria and illustrations for all categories, thereby enabling cytologists to classify each patient case appropriately.
The Establishment of TPS Impacted Pathologists Individually
The current study was conducted 1 year after the establishment of TPS. prior (pre-TPS) and 1 year after (post-TPS) the use of TPS. Institutionally, no significant difference was noted between equivalent diagnostic categories. When atypical rates among individual deidentified pathologists were compared, only 1 pathologist had a significant decrease in their atypical rate (from 25.1% to 18.3%; P<.01) ( Table 2 ).
DISCUSSION
A culture of increased atypical diagnoses among UTC specimens developed at the study institution between 2002 and 2005; this effect was widespread among cytopathologists and was not limited to a few cytopathologists with high atypical rates. The increased atypical rate could be linked to only 2 factors: 1) an increased volume of UTC specimens submitted to the study laboratory; and 2) the arrival of pathologist 3 (Fig. 3) to the study institution. Pathologist 3 had a significantly higher rate of atypical diagnoses compared with other pathologists, which contributed toward the increased institutional rate of atypia. However, the atypical rate of the other pathologists also increased during this time (Fig. 4) , indicating that the increased number of atypical specimens diagnosed by pathologist 3 was not the only factor behind the increased institutional atypical rate.
Because the increase in the atypical rate occurred gradually over time and was not an abrupt shift, it is unlikely that it simply was related to a distinct event in time. For example, we switched from cytospin preparations to SurePath liquid-based preparations for urine specimens in 2004 (Fig. 1) , but the gradual increase in atypical diagnoses occurred both before and after this change. Although we suspected that a gradual increase in patient and/or specimen complexity may have been a factor, the data from the current study do not support this concept. Although the percentage of instrumented specimens did gradually increase over time, this increase occurred during both increases and decreases in the institutional atypical rate (Fig. 2A) . Furthermore, the VU specimen atypical rate closely tracked the atypical rate among all specimens, suggesting that specimen complexity was not a contributing factor. Finally, when we considered patients with an associated diagnosis of HGUC over the study period ("complex patients" in Fig. 2B ), the number of these patients did increase over time, but their specimen atypical rate closely tracked the atypical rate among all specimens, suggesting that patient complexity was not a factor. Therefore, we offer a different possible explanation for the increase in the atypical rate at the study institution, namely that in the absence of a driving force (such as the The actual diagnostic categories used were as follows: For "benign," the categories of "negative for urothelial atypia or malignancy" (JHHT) and "negative for HGUC" (TPS) were used; for "atypical," the categories of "atypical urothelial cells of undetermined significance" (JHHT) and "atypical urothelial cells" (TPS) were used; and for "suspicious," the categories of "atypical urothelial cells, cannot exclude HGUC" (JHHT) and "suspicious for high-grade urothelial carcinoma" (TPS) were used. JHHT or TPS) to regulate the atypical rate, the atypical rate will drift toward a rate defined by the pathologists practicing in a group. Once atypia has been noted in a specimen, it becomes more difficult for a second party to diagnose that specimen as benign. For example, a cytopathologist may be influenced by a specimen screened as atypical by a trainee or cytotechnologist, and therefore be less likely to overturn the screening diagnosis (Fig. 7A) . Furthermore, knowing that the cytotechnologist or trainee is exposed to the practices of other cytopathologists, the cytopathologist may begin to question their own threshold. In this way, passive peer feedback slowly alters pathologist practice patterns over time. Thus, in this manner, it is possible that pathologist 3 (Fig. 3 ) may have gradually driven up the atypical rate of the other pathologists. This phenomenon may have been accelerated due to the increased number of UTC specimens submitted to the laboratory during this period because it provided more opportunities for cytopathologists to compare their diagnoses with others.
The JHHT was established in 2006 and coincided with a decrease in the institutional atypical rate. However, the official establishment of a system is never without a prelude. Initiated by clinician complaints and the realization of pathologists that an atypical diagnosis is counterproductive, informal and formal discussions raise departmental awareness before the acceptance of any reporting system. This explanation is likely the reason why Figure 7 . A model demonstrating how active and passive peer feedback may contribute to changes in atypical rates over time at an academic institution. (A) In the first series, a specimen is screened as benign by the cytotechnologist (CT) and fellow/resident (F/R), and signed out as benign by the cytopathologist (CP). In the second series, the CP makes an "atypical" (Atyp) diagnosis that may impact the F/R at the microscope and/or the CT during CT-CP correlation. In the third series, the F/R disagrees with the CT, most likely assigning an Atyp diagnosis, which may influence the CP's diagnosis. In the fourth series, the CT decides on an Atyp diagnosis, which may influence the F/R and/or the CP. During daily consensus conferences or case sharing, CPs may influence each other's threshold for making an Atyp diagnosis. Gray arrows indicate the potential influence on an individual to decrease their threshold for an Atyp diagnosis. (B) In the second series, the CP overturns the F/R and CT screening diagnosis of Atyp and provides the F/R feedback at the microscope. The CT receives passive feedback during CT-CP correlation. The CP also can provide active feedback to other CPs during consensus conferences. Gray arrows indicate potential passive influence on an individual to increase their threshold for an Atyp diagnosis, and black arrows indicate opportunities for active feedback.
the atypical rate began to decline 1 year before the JHHT. Because publications describing the JHHT in part initiated TPS, discussions of TPS likely lead to changes in practice at JHH before the formal establishment of TPS at the institution in 2016. Therefore, it is not surprising that TPS had little immediate impact on our atypical rate when comparing the 1 year before with the 1 year after TPS because many of the TPS concepts already had been incorporated into our practice years before. In fact, similar results have been reported at Loyola Medical Center, an institution with several pathologists heavily involved in TPS framework. 20 In addition, the decline in the institutional atypical rate at JHH continued for years after the establishment of the JHHT, suggesting that perhaps a decrease in atypia due to the implementation of TPS will be noted over time in the years to come instead of just 1 year's analysis immediately after implementation. Although the JHHT did not establish diagnostic criteria for the atypical category, it coincided with an active discussion regarding UTC specimens at the study institution. With sufficient acceptance, pathologists then may actively convince their peers, trainees, and cytotechnologists to increase their thresholds for an atypical diagnosis (Fig. 7B) . Implementation of the JHHT was accompanied by passive peer feedback and explains the continued reduction in atypical rates noted in the years after its establishment. However, this pattern also predicts a further decrease in the JHH institutional atypical rate due to TPS in the next few years, but only if the pathologist who experienced a significant decline in the atypical rate (pathologist F; Table 2 ) can sufficiently influence his or her peers.
It has been suggested that the atypical rate should vary among institutions based on the pretest probability for HGUC among the patient population. To the best of our knowledge, the "ideal rate" of atypical diagnoses has not been established, although a standardized rate of malignancy (ROM), based on biopsy confirmation, would be the most clinically useful parameter. If an ROM is too low, then specimens might as well be classified as negative for HGUC; if an ROM is too high, then specimens might as well be classified as suspicious for HGUC. 21 Given the data presented in the current study, we believe that our floor for the atypical diagnosis rate is no lower than 10% to 15%. Although this rate may not provide an ROM that can impact clinical decision making, a lowered atypical rate can lead to decreased patient anxiety. The urologists at JHH rely heavily on cytology to supplement endoscopic and radiologic evaluation of the urinary tract to detect clinically significant HGUC. An increased frequency of atypical diagnoses has caused them to become desensitized to the interpretation, resulting in them treating the interpretation clinically in a manner similar to that for "negative" cases. As such, the smaller a laboratory's frequency of "atypical" interpretations, the more meaningful that category is in the clinical management of patients with bladder cancer. For pathologists, the atypical category may remain a useful category with which to track specimens with unusual features rather than relying on the category of "negative for HGUC." A major limitation of the current study is that it was retrospective and descriptive; the comparisons were coincidental and could not prove cause and effect. There is no question that the institutional atypical rate increased by >50% between 1995 and 2005 and then declined between 2005 and 2010. Although we cannot prove reasons for the increase or decline, we propose that in the absence of an actively promoted standardized reporting system, atypical rates will rise due to the individual and subjective use of atypical diagnoses unless pathologists are given feedback and autoregulate the rates of atypia based on patient outcomes. A similar effect was seen in Pap test specimens before The Bethesda System for Reporting Cervical Cytology. 22 An actively promoted system (such as the JHHT) predictably should cause declines in the number of atypical diagnoses. The initial impact of such a system may be felt before its official establishment, whereas the full impact may experience a lag while pathologists adjust to new nomenclature and criteria. With regard to TPS, we believe the initial impact has been lessened by our use of the JHHT, but that an additional impact will be felt with greater understanding and acceptance of TPS among our cytopathologists.
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